[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Thirty-seven parkinsonian patients treated with bromocriptine +/- domperidone were examined eighteen months later. Fifteen continued the same treatment; 10 also received L-DOPA plus a peripheral DOPA-decarboxylase-inhibitor; the others resumed L-DOPA therapy. Thus, by limiting peripheral side effects, domperidone permits effective doses of bromocriptine.
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001562:Benzimidazoles / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D004294:Domperidone; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001562:Benzimidazoles; D010880:Piperidines; D001971:Bromocriptine; D007980:Levodopa; D004294:Domperidone
Résultats à long terme du traitement de la maladie de Parkinson par bromocriptine et dompéridone.